#今日行業(yè)熱點#

①Nature：The breakthrough obesity drugs that have stunned researchers

新一代的抗肥胖藥物顯示效果驚人:體重大幅下降,嚴重副作用更輕
DOI :10.1038/d41586-023-00266-z

②Nature子刊：Multi-antigen spherical nucleic acid cancer vaccines

多抗原癌癥疫苗的結(jié)構(gòu)設(shè)計對其療效有重大影響

DOI :10.1038/s41551-022-01000-2

③柳葉刀子刊綜述：COVID-19患者的抗微生物藥物耐藥性

Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis

DOI:https://doi.org/10.1016/S2666-5247(22)00355-X

④柳葉刀子刊：COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study

接種COVID-19后的橫向流動IgG血清陽性和血清中和抗體應(yīng)答的橫斷面研究

DOI :10.1016/S2666-5247(22)00290-7

⑤Cell子刊：NOVA1 acts on Impact to regulate hypothalamic function and translation in inhibitory neurons

NOVA1結(jié)合Impact mRNA在成人下丘腦神經(jīng)元中通過翻譯和代謝發(fā)揮作用

DOI :10.1016/j.celrep.2023.112050

⑥PLOS Biology：Early transcriptional and epigenetic divergence of CD8+ T cells responding to acute versus chronic infection

CD8+T細胞對急性和慢性感染反應(yīng)的早期轉(zhuǎn)錄和表觀遺傳差異

DOI :10.1371/journal.pbio.3001983

⑦口服核苷類抗新型冠狀病毒1類創(chuàng)新藥VV116生產(chǎn)計劃披露，協(xié)議期10年，預(yù)計獲百億市場

⑧君實生物靶向ANGPTL3信使RNA的siRNA藥物JS401臨床試驗申請獲批，將主要用于高脂血癥等治療

⑨基于對原位鱗狀細胞癌的IIb期研究和對基底細胞癌的II期研究的積極結(jié)果，STP705治療非黑色素瘤皮膚將加速推進臨床開發(fā)

⑩美國食藥監(jiān)局批準開展ASC10治療呼吸道合胞病毒(RSV)感染IIa期臨床試驗，該口服雙前藥或?qū)⒊蔀槿蚴卓钪委熀粑篮习《靖腥镜挠行幬?/span>

?

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！